Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [small RNA-Seq]

ABSTRACT: COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [small RNA-Seq]

PROVIDER: PRJNA951718 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24049400.fastq.gz	Fastqsanger.gz
	SRR24049500.fastq.gz	Fastqsanger.gz
	SRR24049401.fastq.gz	Fastqsanger.gz
	SRR24049501.fastq.gz	Fastqsanger.gz
	SRR24049402.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 180

Similar Datasets

COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease

Project description:COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease

| PRJNA951713 | ENA

COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [Illumina RNA-Seq]

Project description:COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [Illumina RNA-Seq]

| PRJNA951716 | ENA

COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [long-read RNA-Seq]

Project description:COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [long-read RNA-Seq]

| PRJNA951717 | ENA

COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [Illumina RNA-Seq]

Project description:A subset of individualsenrolledina randomised controlled trial ofChAdOx1 nCoV-19 and received either ChAdOx1 COVID-19 or control MenACWY vaccine whoexperienced COVID-19-associated symptoms were evaluated using multi-omictechnologies. Participants were selected to represent symptomatic individuals with and without COVID-19 as determined by a nucleic acid amplification test (NAAT) for stage 1 and only NAAT+ve for stage 2 of the study.

2024-03-04 | GSE228839 | GEO

COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [small RNA-Seq]

2024-03-04 | GSE228841 | GEO

COVID-19 vaccination is associated with attenuation of inflammatory responses during breakthrough disease [long-read RNA-Seq]

2024-03-04 | GSE228840 | GEO

Microarray analysis of healthcare workers that received the COVID-19 mRNA vaccination

Project description:RNA was extracted from whole blood of subjects collected in Tempus tubes prior to COVID-19 mRNA booster vaccination. D01 and D21 correspond to samples collected at pre-dose 1 and pre-dose 2 respectively. RNA was also extracted from blood collected at indicated time points post-vaccination. DB1, DB2, DB4 and DB7 correspond to booster day 1 (pre-booster), booster day 2, booster day 4 and booster day 7 respectively. The case subject experienced cardiac complication following mRNA booster vaccination. We performed gene expression analysis of case versus controls over time.

2023-03-20 | E-MTAB-12829 | biostudies-arrayexpress

Clinical study on the plasma of COVID-19 vaccination and breakthrough infection

Project description:The immune differences between heterologous, homologous immunization and COVID-19 breakthrough infeciton.

2024-04-07 | PXD051245 |

Influenza vaccination reveals sex dimorphic imprints of prior mild COVID-19 [RNA-Seq]

Project description:Acute viral infections can have durable functional impacts on the immune system long after recovery, but how they affect homeostatic immune states and responses to future perturbations remain poorly understood. Here we use systems immunology approaches, including longitudinal multimodal single cell analysis (surface proteins, transcriptome, and V(D)J sequences), to comparatively assess baseline immune statuses and responses to influenza vaccination in 33 healthy individuals after recovery from mild, non-hospitalized COVID-19 (mean: 151 days after diagnosis) and 40 age- and sex-matched controls who never had COVID-19. At baseline and independent of time since COVID-19, recoverees had elevated T-cell activation signatures and lower expression of innate immune genes in monocytes. COVID-19-recovered males had coordinately higher innate, influenza-specific plasmablast, and antibody responses after vaccination compared to healthy male and COVID-19-recovered females, partly because male recoverees had monocytes with higher IL-15 responses early after vaccination coupled with elevated pre-vaccination frequencies of "virtual memory" like CD8+ T-cells poised to produce more IFNg upon IL-15 stimulation. In addition, the expression of the repressed innate immune genes in monocytes increased by day 1 through day 28 post-vaccination in recoverees, thus moving towards the pre-vaccination baseline of healthy controls. In contrast, these genes decreased on day 1 and returned to the baseline by day 28 in controls. Our study reveals sex-dimorphic impacts of prior mild COVID-19 and suggests that viral infections in humans can establish new immunological set-points impacting future immune responses in an antigen-agnostic manner.

2022-03-09 | GSE194378 | GEO

Influenza vaccination reveals sex dimorphic imprints of prior mild COVID-19 [single-cell CITEseq]

2023-01-04 | GSE206265 | GEO